US5914132A
(en)
*
|
1993-02-26 |
1999-06-22 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
US6028190A
(en)
|
1994-02-01 |
2000-02-22 |
The Regents Of The University Of California |
Probes labeled with energy transfer coupled dyes
|
GB9412394D0
(en)
|
1994-06-21 |
1994-08-10 |
Danbiosyst Uk |
Colonic drug delivery composition
|
US6166024A
(en)
*
|
1995-03-30 |
2000-12-26 |
Mayo Foundation For Medical Education And Research |
Use of topical azathioprine and thioguanine to treat colorectal adenomas
|
US6231888B1
(en)
|
1996-01-18 |
2001-05-15 |
Perio Products Ltd. |
Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
|
FR2745500B1
(fr)
*
|
1996-03-04 |
1998-04-03 |
Synthelabo |
Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
|
WO1998022096A1
(en)
*
|
1996-11-15 |
1998-05-28 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
US20060029653A1
(en)
|
1997-01-29 |
2006-02-09 |
Cronk Peter J |
Therapeutic delivery system
|
US6531152B1
(en)
|
1998-09-30 |
2003-03-11 |
Dexcel Pharma Technologies Ltd. |
Immediate release gastrointestinal drug delivery system
|
ATE279914T1
(de)
*
|
1998-11-27 |
2004-11-15 |
Kanji Takada |
Oral anzuwendendes arzneimittel zur wirkstoffverabreichung im magendarmtrakt
|
US6761903B2
(en)
|
1999-06-30 |
2004-07-13 |
Lipocine, Inc. |
Clear oil-containing pharmaceutical compositions containing a therapeutic agent
|
US6294192B1
(en)
|
1999-02-26 |
2001-09-25 |
Lipocine, Inc. |
Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
|
US6267985B1
(en)
|
1999-06-30 |
2001-07-31 |
Lipocine Inc. |
Clear oil-containing pharmaceutical compositions
|
US6632451B2
(en)
|
1999-06-04 |
2003-10-14 |
Dexcel Pharma Technologies Ltd. |
Delayed total release two pulse gastrointestinal drug delivery system
|
CN1173695C
(zh)
*
|
1999-06-14 |
2004-11-03 |
科斯默股份公司 |
控制释放与掩蔽味道的口服药物组合物
|
US6982281B1
(en)
*
|
2000-11-17 |
2006-01-03 |
Lipocine Inc |
Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
|
US6458383B2
(en)
|
1999-08-17 |
2002-10-01 |
Lipocine, Inc. |
Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
US7732404B2
(en)
|
1999-12-30 |
2010-06-08 |
Dexcel Ltd |
Pro-nanodispersion for the delivery of cyclosporin
|
SE0000773D0
(sv)
*
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
New formulation
|
SE0000774D0
(sv)
*
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
New formulation
|
US6365181B1
(en)
|
2000-04-20 |
2002-04-02 |
Gattefosse Corporation |
Thixatropic gelatin carrier composition
|
JP4875277B2
(ja)
|
2000-06-16 |
2012-02-15 |
田辺三菱製薬株式会社 |
放出pH域及び/又は速度制御組成物
|
CA2359812C
(en)
*
|
2000-11-20 |
2004-02-10 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
|
US8206741B2
(en)
|
2001-06-01 |
2012-06-26 |
Pozen Inc. |
Pharmaceutical compositions for the coordinated delivery of NSAIDs
|
DE60237087D1
(de)
*
|
2001-06-01 |
2010-09-02 |
Pozen Inc |
Pharmazeutische zusammensetzungen für die koordinierte abgabe von nsaid
|
SE0102993D0
(sv)
|
2001-09-07 |
2001-09-07 |
Astrazeneca Ab |
New self emulsifying drug delivery system
|
MY148805A
(en)
|
2002-10-16 |
2013-05-31 |
Takeda Pharmaceutical |
Controlled release preparation
|
BRPI0407373B1
(pt)
|
2003-02-12 |
2015-04-22 |
Stiefel Res Australia Pty Ltd |
Composição de espuma hidroalcoólica fotoprotetora e formadora de filme resistente à água
|
US8007827B2
(en)
*
|
2004-04-02 |
2011-08-30 |
Impax Laboratories, Inc. |
Pharmaceutical dosage forms having immediate release and/or controlled release properties
|
US8182840B2
(en)
|
2005-09-27 |
2012-05-22 |
Tissue Tech, Inc. |
Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
|
US8187639B2
(en)
|
2005-09-27 |
2012-05-29 |
Tissue Tech, Inc. |
Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
|
US20070098746A1
(en)
*
|
2005-11-02 |
2007-05-03 |
Nichols William M |
Multi-layered coating technology for taste masking
|
US7858609B2
(en)
|
2005-11-28 |
2010-12-28 |
Marinus Pharmaceuticals |
Solid ganaxolone formulations and methods for the making and use thereof
|
WO2007122478A2
(en)
*
|
2006-04-20 |
2007-11-01 |
Themis Laboratories Private Limited |
Multiple unit compositions
|
US20080014257A1
(en)
*
|
2006-07-14 |
2008-01-17 |
Par Pharmaceutical, Inc. |
Oral dosage forms
|
US20080090897A1
(en)
|
2006-08-11 |
2008-04-17 |
The Johns Hopkins University |
Compositions and methods for neuroprotectin
|
CN101528293A
(zh)
|
2006-08-30 |
2009-09-09 |
戴维·W·史密斯 |
施加单轴或者多轴刚度到挤出的材料的方法以及由此产生的产品
|
CN101610676B
(zh)
|
2006-09-22 |
2013-03-27 |
药品循环公司 |
布鲁顿酪氨酸激酶的抑制剂
|
WO2008122965A2
(en)
|
2007-04-04 |
2008-10-16 |
Sigmoid Pharma Limited |
Pharmaceutical cyclosporin compositions
|
US20090028944A1
(en)
*
|
2007-07-16 |
2009-01-29 |
Balaji Sathurappan |
Pharmaceutical compositions comprising mesalamine
|
US20090036414A1
(en)
*
|
2007-08-02 |
2009-02-05 |
Mutual Pharmaceutical Company, Inc. |
Mesalamine Formulations
|
US8263641B2
(en)
|
2007-09-10 |
2012-09-11 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US20090162434A1
(en)
*
|
2007-12-21 |
2009-06-25 |
Disphar International Bv |
Mesalazine tablet
|
US20090169622A1
(en)
*
|
2007-12-27 |
2009-07-02 |
Roxane Laboratories, Inc. |
Delayed-release oral pharmaceutical composition for treatment of colonic disorders
|
RU2472791C2
(ru)
|
2008-08-27 |
2013-01-20 |
КалсиМедика Инк. |
Соединения, модулирующие внутриклеточный кальций
|
EP2344139A1
(de)
|
2008-09-09 |
2011-07-20 |
AstraZeneca AB |
Verfahren zur abgabe einer pharmazeutischen zusammensetzung an einen patienten, der diese benötigt
|
US20100069887A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Multiple chamber ex vivo adjustable-release final dosage form
|
US20100068278A1
(en)
|
2008-09-16 |
2010-03-18 |
Searete Llc, A Limited Liablity Corporation Of The State Of Delaware |
Ex vivo modifiable medicament release-associations
|
US11304960B2
(en)
|
2009-01-08 |
2022-04-19 |
Chandrashekar Giliyar |
Steroidal compositions
|
DK2421901T3
(en)
|
2009-04-24 |
2016-01-11 |
Tissue Tech Inc |
Compositions comprising HC-HA complex, and methods of use thereof
|
GB2483815B
(en)
|
2009-05-18 |
2013-12-25 |
Sigmoid Pharma Ltd |
Composition comprising oil drops
|
SG176724A1
(en)
|
2009-06-25 |
2012-01-30 |
Astrazeneca Ab |
Method for treating a patient at risk for developing an nsaid-associated ulcer
|
JP5911799B2
(ja)
|
2009-08-12 |
2016-04-27 |
シグモイド・ファーマ・リミテッドSigmoid Pharma Limited |
ポリマーマトリックスおよび油相を含んで成る免疫調節組成物
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
ES2602475T3
(es)
|
2010-04-15 |
2017-02-21 |
Tracon Pharmaceuticals, Inc. |
Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
|
AU2011248579A1
(en)
|
2010-04-27 |
2012-11-29 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
EP2563776B1
(de)
|
2010-04-27 |
2016-06-08 |
Calcimedica, Inc. |
Verbindungen als modulatoren von intrazellulärem calcium
|
NZ702485A
(en)
|
2010-06-03 |
2016-04-29 |
Pharmacyclics Llc |
The use of inhibitors of bruton’s tyrosine kinase (btk)
|
EP2582387A2
(de)
|
2010-06-17 |
2013-04-24 |
The United States Of America As Represented By The Secretary, National Institutes Of Health |
Zusammensetzungen und verfahren zur behandlung von entzündungserkrankungen
|
AU2011293201B2
(en)
|
2010-08-27 |
2015-11-05 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
GB201020032D0
(en)
|
2010-11-25 |
2011-01-12 |
Sigmoid Pharma Ltd |
Composition
|
US20180153904A1
(en)
|
2010-11-30 |
2018-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US9034858B2
(en)
|
2010-11-30 |
2015-05-19 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US9358241B2
(en)
|
2010-11-30 |
2016-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US20120148675A1
(en)
|
2010-12-10 |
2012-06-14 |
Basawaraj Chickmath |
Testosterone undecanoate compositions
|
WO2012149486A1
(en)
|
2011-04-28 |
2012-11-01 |
Tissuetech, Inc. |
Methods of modulating bone remodeling
|
CA2837878A1
(en)
|
2011-06-10 |
2012-12-13 |
Tissuetech, Inc. |
Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
JP2014529630A
(ja)
|
2011-09-07 |
2014-11-13 |
ザウラー−ブロシュ、ローラント |
哺乳類の消化管における一つあるいは複数の物質の放出制御製剤
|
US10653631B2
(en)
|
2011-09-07 |
2020-05-19 |
Roland SAUR-BROSCH |
Optimal colon targeting technology
|
EP2755648B1
(de)
|
2011-09-13 |
2017-03-08 |
Pharmacyclics LLC |
Formulierungen des histondeacetylase-inhibitors in kombination mit bendamustin und verwendungen davon
|
EP2797600A4
(de)
|
2011-12-28 |
2015-09-16 |
Pozen Inc |
Verbesserte zusammensetzungen und verfahren zur abgabe von omeprazol und acetylsalicylsäure
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
SI2800565T1
(sl)
|
2012-01-06 |
2020-10-30 |
Lundbeck La Jolla Research Center, Inc. |
Karbamatne spojine in metode izdelave in uporabe le-teh
|
JP2012107058A
(ja)
*
|
2012-02-27 |
2012-06-07 |
Warner Chilcott Co Llc |
複数のコーティングを有する医薬剤形
|
DK2830599T3
(en)
|
2012-03-29 |
2018-10-08 |
Therabiome Llc |
SITE-SPECIFIC GASTROINTESTINAL ORAL VACCINE FORMS WITH EFFECTS ON ILEUM AND APPENDIX
|
CA2991994C
(en)
|
2012-06-04 |
2022-06-28 |
Pharmacyclics Llc |
Pharmaceutical formulation for oral administration comprising ibrutinib
|
GB201212010D0
(en)
|
2012-07-05 |
2012-08-22 |
Sigmoid Pharma Ltd |
Formulations
|
US10040821B2
(en)
|
2012-07-11 |
2018-08-07 |
Tissuetech, Inc. |
Compositions containing HC-HA/PTX3 complexes and methods of use thereof
|
WO2014052914A1
(en)
|
2012-09-28 |
2014-04-03 |
University Of Washington Through Its Center For Commercialization |
Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
|
US9512116B2
(en)
|
2012-10-12 |
2016-12-06 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
CA3101218A1
(en)
|
2013-03-14 |
2014-09-25 |
Therabiome, Llc |
Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
|
AU2014239683B2
(en)
|
2013-03-15 |
2018-05-17 |
Allergan Pharmaceuticals International Limited |
Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability
|
US9611263B2
(en)
|
2013-10-08 |
2017-04-04 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
JP6165022B2
(ja)
*
|
2013-10-30 |
2017-07-19 |
株式会社ファンケル |
放出制御型ソフトカプセル剤
|
GB201319791D0
(en)
|
2013-11-08 |
2013-12-25 |
Sigmoid Pharma Ltd |
Formulations
|
JP6345786B2
(ja)
|
2013-12-05 |
2018-06-20 |
ファーマサイクリックス エルエルシー |
ブルトン型チロシンキナーゼの阻害剤
|
EP3134418A4
(de)
|
2014-04-23 |
2018-01-03 |
The Research Foundation for The State University of New York |
Schnelle und effiziente reaktion zur bioorthogonalen reaktion und borhaltige, zusammen damit nützliche heterocyclen
|
US10570169B2
(en)
|
2014-05-22 |
2020-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
TW201603818A
(zh)
|
2014-06-03 |
2016-02-01 |
組織科技股份有限公司 |
組成物及方法
|
US20170246187A1
(en)
|
2014-08-28 |
2017-08-31 |
Lipocine Inc. |
(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
|
US9498485B2
(en)
|
2014-08-28 |
2016-11-22 |
Lipocine Inc. |
Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
|
US9839644B2
(en)
|
2014-09-09 |
2017-12-12 |
ARKAY Therapeutics, LLC |
Formulations and methods for treatment of metabolic syndrome
|
HUE053624T2
(hu)
|
2014-11-07 |
2021-07-28 |
Sublimity Therapeutics Ltd |
Ciklosporint tartalmazó készítmények
|
US9359316B1
(en)
|
2014-11-25 |
2016-06-07 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
DK3253766T3
(da)
|
2015-02-06 |
2019-12-09 |
Univ Washington |
Forbindelser og fremgangsmåder til forebyggelse eller behandling af sansehårscelledød
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
US20160243288A1
(en)
|
2015-02-23 |
2016-08-25 |
Tissuetech, Inc. |
Apparatuses and methods for treating ophthalmic diseases and disorders
|
WO2016138479A1
(en)
|
2015-02-27 |
2016-09-01 |
Curtana Pharmaceuticals, Inc. |
Inhibition of olig2 activity
|
PT3265084T
(pt)
|
2015-03-03 |
2024-02-13 |
Pharmacyclics Llc |
Formulações farmacêuticas de inibidor de tirosina cinase de bruton
|
MA41827A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
|
MA41828A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
|
BR112017024253A2
(pt)
|
2015-05-11 |
2018-07-24 |
Abide Therapeutics Inc |
métodos de tratamento de inflamação ou dor neuropática.
|
JP2018516869A
(ja)
|
2015-05-20 |
2018-06-28 |
ティッシュテック,インク. |
上皮細胞の増殖および上皮間葉転換を防ぐための組成物および方法
|
WO2017040617A1
(en)
|
2015-08-31 |
2017-03-09 |
Pharmacyclics Llc |
Btk inhibitor combinations for treating multiple myeloma
|
US20180185378A1
(en)
*
|
2017-01-05 |
2018-07-05 |
Cormedix Inc. |
Antimicrobial delivery system for the prevention and treatment of infections in the colon
|
EP3162362A1
(de)
*
|
2015-10-30 |
2017-05-03 |
Dr. Falk Pharma Gmbh |
Optimierte mesalazinhaltige hochdosistablette
|
DK3827838T3
(da)
|
2015-12-16 |
2023-06-26 |
Walter & Eliza Hall Inst Medical Res |
Hæmning af cytokin-induceret sh2-protein i nk-celler
|
CA3008338A1
(en)
|
2016-01-19 |
2017-07-27 |
Janssen Pharmaceutica Nv |
Formulations/compositions comprising a btk inhibitor
|
EA201891664A1
(ru)
|
2016-01-19 |
2019-02-28 |
Янссен Фармацевтика Нв |
Составы/композиции, содержащие ингибитор btk
|
TW201733600A
(zh)
|
2016-01-29 |
2017-10-01 |
帝聖工業公司 |
胎兒扶持組織物及使用方法
|
WO2017147146A1
(en)
|
2016-02-23 |
2017-08-31 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic trpv1 agonists
|
CN109310700A
(zh)
|
2016-04-04 |
2019-02-05 |
希诺皮亚生物科学公司 |
使用曲匹地尔治疗锥体外系综合征
|
CN109562281B
(zh)
|
2016-05-25 |
2021-12-17 |
同心镇痛药物公司 |
酚类trpv1激动剂的前药与局部麻醉药和血管收缩剂联合用于改善局部麻醉
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205769A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
PT3484862T
(pt)
|
2016-07-18 |
2021-11-17 |
Arthrosi Therapeutics Inc |
Compostos, composições e métodos para o tratamento ou a prevenção de um sintoma associado a gota ou hiperuricemia
|
CN115215807A
(zh)
|
2016-08-26 |
2022-10-21 |
科泰纳制药公司 |
Olig2活性的抑制
|
WO2018093950A1
(en)
|
2016-11-16 |
2018-05-24 |
Abide Therapeutics, Inc. |
Pharmaceutical formulations
|
LT3541807T
(lt)
|
2016-11-16 |
2021-12-27 |
H. Lundbeck A/S |
Magl inhibitoriaus kristalinė forma
|
EP3544614A4
(de)
|
2016-11-28 |
2020-08-05 |
Lipocine Inc. |
Orale testosteron-undecanoat-therapie
|
TWM553193U
(zh)
*
|
2017-06-22 |
2017-12-21 |
Guang De Li Capsules Co Ltd |
耐酸膜衣膠囊結構
|
EP3675865A4
(de)
|
2017-09-01 |
2021-06-02 |
University of Washington |
Kristalline formen von verbindungen zur vorbeugung oder behandlung von sensorischem haarzelltod
|
US11685722B2
(en)
|
2018-02-28 |
2023-06-27 |
Curtana Pharmaceuticals, Inc. |
Inhibition of Olig2 activity
|
AU2019310118A1
(en)
|
2018-07-27 |
2021-03-11 |
Concentric Analgesics, Inc. |
Pegylated prodrugs of phenolic TRPV1 agonists
|
EP3906026A4
(de)
|
2018-12-31 |
2022-10-19 |
Biomea Fusion, LLC |
Irreversible inhibitoren der menin-mll-interaktion
|
CA3133093A1
(en)
|
2019-03-15 |
2020-09-24 |
Unicycive Therapeutics, Inc. |
Nicorandil derivatives
|
JP2022531012A
(ja)
|
2019-05-03 |
2022-07-05 |
アゾーラ セラピューティクス,インコーポレイテッド |
インジゴ及び/又はインジゴ誘導体を含む組成物並びにその使用の方法
|
WO2020243393A1
(en)
*
|
2019-05-30 |
2020-12-03 |
Vta Labs, Llc |
Design of a single oral delivery system containing a monoclonal antibody for the simultaneous treatment of chron's disease and ulcerative colitis
|
JP2023523219A
(ja)
|
2020-04-21 |
2023-06-02 |
ハー・ルンドベック・アクチエゼルスカベット |
モノアシルグリセロールリパーゼ阻害剤の合成
|
CA3202151A1
(en)
|
2020-12-16 |
2022-06-23 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin-mll interaction
|
CA3204457A1
(en)
|
2021-01-06 |
2022-07-14 |
Ben SESSA |
Mdma in the treatment of alcohol use disorder
|
WO2022238507A1
(en)
|
2021-05-11 |
2022-11-17 |
Awakn Ls Europe Holdings Limited |
Therapeutic aminoindane compounds and compositions
|
WO2022256720A2
(en)
|
2021-06-03 |
2022-12-08 |
Arcadia Medicine, Inc. |
Enantiomeric entactogen compositions and methods of their use
|
WO2023018825A1
(en)
|
2021-08-11 |
2023-02-16 |
Biomea Fusion, Inc. |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
AU2022331496A1
(en)
|
2021-08-20 |
2024-02-29 |
Biomea Fusion, Inc. |
Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
|
WO2023027966A1
(en)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as irreversible inhibitors of flt3
|
WO2023039240A1
(en)
|
2021-09-13 |
2023-03-16 |
Biomea Fusion, Inc. |
IRREVERSIBLE INHIBITORS OF KRas
|
WO2023086341A1
(en)
|
2021-11-09 |
2023-05-19 |
Biomea Fusion, Inc. |
Inhibitors of kras
|
US11945785B2
(en)
|
2021-12-30 |
2024-04-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as inhibitors of FLT3
|
WO2023139163A1
(en)
|
2022-01-19 |
2023-07-27 |
Awakn Ls Europe Holdings Limited |
1,3-benzodioxole esters and their therapeutic use
|
WO2023156565A1
(en)
|
2022-02-16 |
2023-08-24 |
Awakn Ls Europe Holdings Limited |
Bridged ring compounds and their therapeutic use as cns agents
|
WO2023235618A1
(en)
|
2022-06-03 |
2023-12-07 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|
WO2024011142A1
(en)
|
2022-07-06 |
2024-01-11 |
Oppilan Pharma Limited |
Crystalline forms of an s1p receptor modulator
|